The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Abbvie Inc shares valued at $13,231,264 were purchased by Richard A. Gonzalez on Aug 22 ’25. At $210.84 per share, Richard A. Gonzalez acquired 62,755 shares.
Also, Richard A. Gonzalez purchased 90,000 shares, netting a total of over 18,993,948 in proceeds.
Before that, SALEKI-GERHARDT AZITA had sold 42,370 shares from its account. In a trade valued at $8,407,055, the EVP, CHIEF OPERATIONS OFFICER traded Abbvie Inc shares for $198.42 each. Upon closing the transaction, the insider’s holdings decreased to 42,370 shares, worth approximately $40.11 million.
As published in a research note from Erste Group on October 14, 2025, Abbvie Inc [ABBV] has been rated down from a Buy to a Hold. Analysts at HSBC Securities downgraded the stock from ‘”a Buy”‘ to ‘”a Hold”‘ outlook in a report released in early October. As of September 17, 2025, Berenberg has increased its “Hold” rating to a “Buy” for ABBV.
Analyzing ABBV Stock Performance
On last trading session, Abbvie Inc [NYSE: ABBV] plunged -1.27% to $226.22. The stock’s lowest price that day was $225.36, but it reached a high of $228.95 in the same session. During the last five days, there has been a drop of approximately -2.17%. Over the course of the year, Abbvie Inc shares have jumped approximately 16.49%.
Is Abbvie Inc subject to short interest?
Stocks of Abbvie Inc saw a sharp rise in short interest on 2025-09-30 jumping by 0.89 million shares to 16.29 million. Data from Yahoo Finance shows that the short interest on 2025-08-29 was 15.4 million shares. A jump of 5.48% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 2.96 of the overall float, the days-to-cover ratio (short ratio) jumped to 2.96.
Which companies own the most shares of Abbvie Inc (ABBV)?
In terms of Abbvie Inc share price expectations, FactSet research, analysts set an average price target of 250.5 in the next 12 months, up nearly 9.33% from the previous closing price of $229.13. Analysts anticipate Abbvie Inc stock to reach 284 by 2025, with the lowest price target being 225. In spite of this, 27 analysts ranked Abbvie Inc stock as Buy at the end of 2025. On August 07, 2025, Daiwa Securities assigned a price target of “an Outperform” to the stock and upgraded coverage with a $214.
